Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Fistula Plug in Perianal Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Males and females 18-65 years of age.~* Residents of the United States.~* Crohn's disease with single or multiple draining complex perianal fistulae (definition as below) for at least three months despite standard therapy (definition below).~* Concurrent therapies with corticosteroids, 5-ASA drugs, thiopurines, MTX, antibiotics, and anti-TNF therapy are permitted.~* All patients should have undergone a colonoscopy in last 12 months to rule out malignant or premalignant condition~* Have no contraindications to MR evaluations: e.g. pacemaker or magnetically active metal fragments, claustrophobia~* Ability to comply with protocol~* Competent and able to provide written informed consent~* Must have failed standard medical therapy including anti-TNF agents~Exclusion Criteria~* Inability to give informed consent.~* Clinically significant medical conditions within the six months before administration of MSCs: e.g. myocardial infarction, active angina, congestive heart failure or other conditions that would, in the opinion of the investigators, compromise the safety of the patient.~* Specific exclusions: Evidence of hepatitis B, C, or HIV~* History of cancer including melanoma (with the exception of localized skin cancers)~* Investigational drug within thirty (30) days of baseline~* A resident outside the United States~* Pregnant or breast feeding.~* History of clinically significant auto-immunity (other than Crohn's disease) or any previous example of fat-directed autoimmunity~* Previous allergic reaction to a perianal fistula plug.~* If liposuction is not technically feasible~* Allergic to local anesthetics~* Pregnant patients or trying to become pregnant.~* Non-enterocutaneous tracts (ie recto-vaginal, entero-vesicular)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Only 1 arm: treatment with MSC-AFP

Based on this trial design, predict the completion outcome and termination type (if applicable).